Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Top Cited Papers
- 30 April 2014
- journal article
- research article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 13 (7), 657-665
- https://doi.org/10.1016/s1474-4422(14)70068-7
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- PEGylation of Interferon-β-1aCNS Drugs, 2012
- The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational studyBMC Neurology, 2011
- A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease typeClinical Therapeutics, 2010
- One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosisEuropean Journal of Neurology, 2009
- Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?Expert Opinion on Drug Delivery, 2009
- Quality of life in 1000 patients with early relapsing–remitting multiple sclerosisEuropean Journal of Neurology, 2009
- PEG-modified biopharmaceuticalsExpert Opinion on Drug Delivery, 2009
- N-Terminally PEGylated Human Interferon-β-1a with Improved Pharmacokinetic Properties and in Vivo Efficacy in a Melanoma Angiogenesis ModelBioconjugate Chemistry, 2005
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Rating neurologic impairment in multiple sclerosisNeurology, 1983